Alzamend Neuro
ALZNPhase 2Alzamend Neuro® is a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease, Bipolar disorder, Major Depressive Disorder (“MDD”) and Post-Traumatic Stress Disorder (“PTSD”). Our mission is to rapidly develop and market safe and effective treatments to bring aid to the 43+ Million Americans suffering from these debilitating diseases. Our current pipeline consists of two novel therapeutic drug candidates, AL001 – a patented ionic c...
ALZN · Stock Price
Historical price data
About
Alzamend Neuro® is a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease, Bipolar disorder, Major Depressive Disorder (“MDD”) and Post-Traumatic Stress Disorder (“PTSD”). Our mission is to rapidly develop and market safe and effective treatments to bring aid to the 43+ Million Americans suffering from these debilitating diseases. Our current pipeline consists of two novel therapeutic drug candidates, AL001 – a patented ionic c...
Pipeline Snapshot
33 drugs in pipeline
| Drug | Indication | Stage |
|---|---|---|
| AL001 | Alzheimer's Disease | Phase 1/2 |
| ALZN002 (autologous DCs pulsed with E22W mutant peptide). + Placebo | Alzheimer Disease | Phase 1/2 |
| AL001 + Lithium Carbonate Capsule | Pharmacokinetics | Phase 1 |
Funding History
4Total raised: $32.5M
Company Info
Contact
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile